Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory trial of Comboprofen for delayed onset muscle soreness (DOMS)
2016-003139-39Phase 2Active
- Sponsor
- Spherium Biomed
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of comboprofen in delayed onset muscle soreness (DOMS) (5 arms), sponsored by Spherium Biomed. Primary endpoint: SPID while walking over first 72 hours. Started Mar 2017; status: active.
02
Drugs
comboprofen
03
Conditions
delayed onset muscle soreness (DOMS)
Beyond the preview
Go deeper on 2016-003139-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003139-39.